ERBB2 and neoplasm: This toxicity was speculated to be triggered by the low level of HER-2 expressed on the lung epithelial cells.3 CAR-T cell immunotherapy can be genetically engineered to minimize the deleterious damages of on-target / off-tumour toxicities (or bystander healthy tissue damages) to mitigate life-threatening toxicities and achieve successful development in solid tumours.